ABT - Abbott Laboratories
56.32 0.00 (0.00%)
After hours: 4:33PM EDT
| Previous Close | 56.00 |
| Open | 56.17 |
| Bid | 56.29 x 100 |
| Ask | 56.45 x 100 |
| Day's Range | 55.94 - 56.44 |
| 52 Week Range | 37.38 - 56.60 |
| Volume | 5,482,613 |
| Avg. Volume | 5,584,870 |
| Market Cap | 97.85B |
| Beta | 1.65 |
| PE Ratio (TTM) | 78.88 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.06 (1.94%) |
| Ex-Dividend Date | 2017-10-12 |
| 1y Target Est | N/A |
- Market Realist•2 hours ago
Abbott Laboratories Stock: Performance in 3Q17
Abbott Laboratories stock has risen ~9.7% in 3Q17. It has risen 45.8% year-to-date as of October 20, 2017.
- The Wall Street Journal•11 hours ago
[$$] Hacking Is a Risk for Pacemakers. So Is the Fix
A new software patch to fix a cybersecurity weakness in pacemakers has raised a dilemma among doctors and patients: Is the fix worth the risk?
Motley Fool•yesterdayAbbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)
ABT earnings call for the period ending September 30, 2017
- TheStreet.com•yesterday
My Rx: Keep Holding Abbott Labs Longs
The drugmaker is in an uptrend with a price target of $60.
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of ABT earnings conference call or presentation 18-Oct-17 1:00pm GMT
Q3 2017 Abbott Laboratories Earnings Call
- Investor's Business Daily•2 days ago
Abbott Delivers $100 Million Sales Beat On Pharma, Devices Strength
Abbott Laboratories delivered a sales beat in the third quarter, helped by its pharmaceutical and medical devices units.
- Zacks•2 days ago
Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed
Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.
- Reuters•2 days ago
Abbott's recent deals, medical device pipeline to fuel growth
Abbott Laboratories' quarterly results beat estimates and the company raised the top end of its full-year earnings forecast range on Wednesday, as a string of recent deals and medical device approvals help spur growth in its largest unit. The company has acquired several rivals this year, including St. Jude Medical and Alere, to bolster its medical devices business, and favorable tax laws in India are boosting its generics business. Strength in medical devices pulled this quarter, while recent product approvals puts Abbott in a good position, Jefferies analyst Raj Denhoy told Reuters.
- Reuters•2 days ago
Abbott's recent deals, medical device pipeline to fuel growth
Abbott Laboratories' quarterly results beat estimates and the company raised the top end of its full-year earnings forecast range on Wednesday, as a string of recent deals and medical device approvals help spur growth in its largest unit. The company has acquired several rivals this year, including St. Jude Medical and Alere, to bolster its medical devices business, and favorable tax laws in India are boosting its generics business. Strength in medical devices pulled this quarter, while recent product approvals puts Abbott in a good position, Jefferies analyst Raj Denhoy told Reuters.
- MarketWatch•2 days ago
Abbott shares surge 1.6% after Q3 profit, revenue beats
Abbott Laboratories shares surged 1.6% in morning trade Wednesday after the company reported third-quarter profit and revenue beats. Earnings for the latest quarter were $603 million, or 32 cents per share, ...
- Zacks•2 days ago
Abbott (ABT) Beats Earnings and Sales in Q3, Tweaks View
Abbott (ABT) rides high on strength in all segments in Q3 earnings.
Markit•2 days agoSee what the IHS Markit Score report has to say about Abbott Laboratories.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. ABT credit default swap spreads are within the middle of their range for the last three years.
- Reuters•2 days ago
Abbott Labs posts quarterly profit vs. year-ago loss
Diversified healthcare company Abbott Laboratories on Wednesday reported a quarterly profit compared with a loss in the year-ago quarter, helped by strong sales in its medical devices and generics businesses. ...
- Associated Press•2 days ago
Abbott tops Street 3Q forecasts
The Abbott Park, Illinois-based company said it had profit of 34 cents per share. Earnings, adjusted for one-time gains and costs, were 66 cents per share. The results exceeded Wall Street expectations. ...
- TheStreet.com•2 days ago
IBM, China and Dow 23,000 - 5 Things You Must Know Before the Market Opens
U.S. stock futures are higher on Wednesday, with the Dow Jones Industrial Average poised to open around 23,000.
- Yahoo Finance•3 days ago
Beige Book, AmEx, and eBay — What you need to know on Wednesday
The Federal Reserve, American Express, and eBay will be the big stories on Wednesday as tax reform continues to dominate the Washington-related headlines.
- Zacks•3 days ago
Phibro Animal Banks on Diverse Portfolio, Competition Rife
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
- Zacks•3 days ago
Henry Schein (HSIC) Inks Distribution Agreement with Terason
Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.
- Zacks•3 days ago
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare
- Zacks•4 days ago
Top Research Reports for AbbVie, American Express & Abbott
Top Research Reports for AbbVie, American Express & Abbott
- Zacks•4 days ago
Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now
Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.
- CNBC Videos•22 hours ago
Maneuvering the market sell-off
Jim Cramer pinpoints the windows of opportunity in the market-wide sell-off and helps investors strategize how to play the decline.
- CNBC Videos•22 hours ago
Cramer shares his playbook for maneuvering the market sel...
Jim Cramer pinpoints the windows of opportunity in the market-wide sell-off and helps investors strategize how to play the decline.
